However, progression free survival and overall survival are poor in patients with MYC translocations after treatment with standard immunochemotherapy for DLBCL (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP)) [11,12,13,14,15,16]. Here, MYC is linked to diffuse large B-cell lymphoma.